Plenaxis (abarelix for injectable suspension)

On May 20, 2005, Praecis Pharmaceuticals announced that it is voluntarily discontinuing the sale of Plenaxis to new patients in the United States for economic reasons.

• Letter from Praecis: Dear Hospital Pharmacy (5/26/2005)
• Letter from Praecis: Dear Healthcare Provider (5/26/2005)

Background Information

• FDA Talk Paper (11/25/2003)
• Questions and Answers (11/25/2003)
• Patient Package Insert Optional Format: PDF (11/25/2003)
• Prescribing Information
• Hospital Pharmacy's Acceptance of Responsibilities
• Physician Attestation of Qualifications and Acceptance of Prescribing Responsibilites

PDF requires the free Adobe Acrobat Reader

Back to Top     Drug Information

Date created: November 25, 2003, updated May 31, 2005

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page

FDA/Center for Drug Evaluation and Research